Not logged inA Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)
Aroldi, Francesca; Elez, Elena; Andre, Thierry; Perkins, Geraldine; Prenen, Hans; Popovici, Vlad; Gallagher, Peter; Houlden, Jennifer; Collins, Linda; Roberts, Corran; Rolfo, Christian; Di Nicolantonio, Federica; Grayson, Margaret; Boyd, Ruth; Bettens, Karolien; Delfavero, Jurgen; Coyle, Victoria; Lawler, Mark; Khawaja, Hajrah; Laurent-Puig, Pierre; Salto-Tellez, Manuel; Maughan, Tim S.; Tabernero, Josep; Adams, Richard; Jones, Robert; Hennessy, Bryan T.; Bardelli, Alberto; Peeters, Marc; Middleton, Mark R.; Wilson, Richard H.; Van Schaeybroeck, Sandra .png)
Share.png)
SavePhase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutationDesai, Jayesh; Han, Sae-Won; Lee, Jong-Seok; Shacham-Shmueli, Einat; Massarelli, Erminia; Cervantes, Andres; Garralda, Elena; Falcon, Alejandro; Miller, Wilson H.; Gort, Eelke; Karasic, Thomas; Siena, Salvatore; Stec, Rafal; Medina, Laura; Paz-Arez, Luis; Delmonte, Angelo; Sacher, Adrian; Prenen, Hans; Forster, Martin; Kim, Tae Won; Krebs, Matthew G.; Cosman, Rasha; Choi, Yoonha; Mandlekar, Sandhya; Lin, Mark T.; Yau, Kenneth K.; Chang, Julie; Royer-Joo, Stephanie; Dharia, Neekesh V.; Schutzman, Jennifer L.; Patel, Manish Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
